Developer docs
API playgroundTry for free, no card

Search company profiles

iktos-dev

Full company profile

uuid02m3rmd

Namestring
iktos-dev
Legal namestring
Iktos SA
Websiteurl
iktos.com
Company typeenum
Private
Founded yearint
2016
Descriptiontext

Iktos is a Paris-based AI and robotics company founded in 2016 that develops an integrated platform for small-molecule drug discovery spanning the full Design-Make-Test-Analyze (DMTA) cycle. Its three core products are Makya, a generative AI SaaS platform trained on millions of reactions that designs novel, synthetically accessible molecules with multi-parametric optimization across potency, selectivity, and ADMET properties; Spaya, an AI-driven retrosynthesis engine using reinforcement learning and Monte Carlo Tree Search to convert targets into commercially available starting materials in seconds; and Ilaka, an AI orchestration layer that transforms virtual molecules into executable instructions for Chemspeed robotic systems running 100+ reactions per day across 55+ named reactions. The Iktos Robotics Biology platform adds high-throughput phenotypic screening via the proprietary MTBench technology for protein-protein, RNA-protein, and molecular glue/PROTAC discovery, and the Iktos Engine APIs extend the stack with production-ready 3D design tools (Iktos 3D Align, Iktos 3D Dock, Boltz 3D Affinity).

The company generates revenue through three streams: SaaS subscriptions for Makya and Spaya (web and API access), fee-for-service and co-development drug discovery collaborations with pharmaceutical, biotech, and academic partners, and technology licensing — including transfer of Ilaka to pharma partners running Chemspeed robots. Pricing is quote-based and not publicly disclosed. Since founding, Iktos reports 60+ collaborations with major pharmaceutical companies (Merck, Pfizer, Servier, Janssen, Takeda, Pierre Fabre, Italfarmaco), biotech firms (Cube Biotech, Sygnature Discovery), and academic institutions, with one Servier strategic collaboration carrying potential total value exceeding €1 billion. Following a €15.5M Series A in 2023, Iktos has expanded into in-house drug discovery, maintaining a pipeline across MTHFD2 (inflammation/autoimmune), Amylin receptor (obesity/metabolism), and SKP2-CKS1 (immuno-oncology). Operations span Europe (Paris HQ), the United States, and Japan/APAC (Iktos K.K. subsidiary).

Short descriptiontext

Iktos is a Paris-based AI and robotics company developing Makya (generative AI drug design), Spaya (AI retrosynthesis), and Ilaka (robotic lab orchestration) into an integrated small-molecule drug discovery platform serving pharmaceutical, biotech, and academic partners globally.

Operating statusenum
Operating
Ownership categoryenum
akta.pro rankint
HeadquartersParis, France
HQ citystring
Paris
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
generative AI drug design, AI retrosynthesis planning, automated drug discovery, AI-orchestrated laboratory automation, computational chemistry platforms
Industry1 code
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Computer Systems Design Services541512
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • Services-Computer Integrated Systems Design7373
Product category
AI-Driven Drug Discovery Software
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Drug Discovery Collaborations
TypeProfessional Services
Description

Fee-for-service and co-development collaborations with pharmaceutical, biotech, and academic institutions for drug discovery programs. Partners engage Iktos to access AI-driven generative design, retrosynthesis planning, and robotic synthesis capabilities to advance their own programs from hit discovery through lead optimization. Collaboration structure includes both transactional service fees and potentially co-development arrangements with milestone payments.

iktos.ai
2SaaS Platform Subscriptions (Makya, Spaya)
TypeSubscription Recurring
Description

Subscription-based access to Makya (generative AI drug design SaaS) and Spaya (AI-driven retrosynthesis SaaS) platforms. Platforms available via web interface and API access. Spaya API enables high-throughput scoring of synthetic feasibility for computational chemistry pipelines. Pricing likely subscription-based with potential usage-based API components.

iktos.ai
3Technology Licensing and Integration
TypeLicensing Royalties
Description

Licensing of Iktos technologies including Ilaka orchestration software for integration with third-party robotic platforms, and Spaya API for embedding in partner workflows. Technology transfer to pharmaceutical partners for deployment of AI-driven synthesis workflows.

iktos.ai
Marketing channels9 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels6 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Infrastructure, Marketing or Sales, Operations
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

Iktos develops and sells an integrated AI and robotics platform for small-molecule drug discovery. Its core offerings are the Makya generative AI SaaS for de novo molecular design, the Spaya AI-driven retrosynthesis SaaS, the Ilaka orchestration software that connects designs to Chemspeed robotic synthesis, and the Iktos Engine APIs for 3D drug design. The platform enables pharmaceutical and biotech partners to execute the full Design-Make-Test-Analyze (DMTA) cycle.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 7 values shown
  • Discovery phase timeline reduced from 4-5 years to under 2 years for preclinical candidate identification
+6 more records
Product overview1 text field

Iktos offers an integrated AI and robotics platform for drug discovery comprising three core products: Makya (generative AI for de novo molecular design), Spaya (AI-driven retrosynthesis planning), and Ilaka/Iktos Robotics (AI-orchestrated laboratory automation). The platform operates as a unified DMTA (Design-Make-Test-Analyze) cycle, where Makya generates optimized molecules, Spaya identifies synthesis routes, and Ilaka coordinates robotic execution. Additional offerings include Iktos Engine APIs for 3D drug design and MTBench for phenotypic screening. The company also maintains an internal pipeline of drug candidates in oncology, inflammation, and metabolism.

Product and service5 records
1Makya
CategoryGenerative AI Drug Design Software
Description

Makya is a generative AI SaaS platform for de novo small-molecule drug design. It creates diverse, novel, and synthetically accessible medchem-like molecules using multi-parametric optimization, 3D ligand-based and structure-based modeling, SAR modeling, and ADMET property optimization. It is targeted at medicinal and computational chemistry teams in pharmaceutical and biotech companies.

2Spaya
CategoryAI Retrosynthesis Software
Description

Spaya is an AI-driven retrosynthesis SaaS platform that identifies feasible synthetic routes by converting target compounds into commercially available starting materials in seconds. It uses reinforcement learning and Monte Carlo Tree Search, supports 35+ provider partnerships, 2000+ named reactions, customizable constraints, and chirality handling. It is used by computational chemistry teams in pharma and biotech for synthetic feasibility scoring.

3Ilaka
CategoryLaboratory Automation Orchestration Software
Description

Ilaka is an AI-driven laboratory orchestration software that transforms virtual molecules into executable instructions for Chemspeed robotic systems. It orchestrates the full decision workflow from retrosynthesis and reaction selection to reagent sourcing, experimental procedures, and synthesis scheduling, including AI-driven reaction clustering for parallel execution. It is licensed to pharmaceutical partners seeking to deploy AI-orchestrated laboratory automation.

4Iktos Engine APIs
Category3D Drug Design APIs
Description

Iktos Engine APIs are production-ready APIs for 3D drug design workflows. The suite includes Iktos 3D Align for template-based ligand alignment, Iktos 3D Dock for pocket-aware template-based docking, and Boltz 3D Affinity for binding affinity prediction. The APIs address ligand-based and structure-based design decisions across hit-to-lead optimization projects and integrate with Knime, Pipeline Pilot, and Jupyter Notebook.

5Iktos Robotics Chemistry and Biology
CategoryAutomated Laboratory Robotics
Description

Iktos Robotics is a fully automated synthesis, purification, and analysis platform using Chemspeed robotics, capable of running 100 reactions per day in parallel across more than 55 different named reactions. Iktos Robotics Biology includes high-throughput phenotypic assays using patented Microtubule Bench technology for in-cellulo screening of protein-protein interactions, RNA-protein interactions, and molecular glues/PROTACs.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership9 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-03-26
Description

Collaboration to offer pharmaceutical partners a solution combining advanced synthesis planning and orchestration AI software with Chemspeed robotics for chemical synthesis execution. Iktos makes available the Ilaka AI-driven laboratory orchestration technology developed for the Chemspeed chemistry automation platform. Ilaka transforms virtual molecules into executable instructions for Chemspeed robotic systems, orchestrating the full decision workflow from retrosynthesis to reagent sourcing, experimental procedures, and synthesis scheduling. Partnership enables technology transfer to pharmaceutical partners seeking to deploy AI-orchestrated laboratory automation.

2Elsevier (Reaxys)
Strategic tierCoreTypeTechnology or Integration
Description

Strategic partnership combining the world's largest chemistry database Reaxys with Iktos's cutting-edge AI retrosynthesis technology to create new predictive retrosynthesis and synthetic accessibility tools. Integrates Elsevier's chemistry data infrastructure with Iktos's Spaya platform capabilities.

iktos.ai
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partnership to co-develop novel Amylin receptor agonists for obesity and cardiometabolic disorders. Cube's cutting-edge protein stabilization technology preserves the natural conformation of membrane proteins, enabling access to biologically active drug targets. Combined with Iktos's AI-driven drug discovery platform, this collaboration aims to accelerate development of breakthrough small molecule therapies targeting the Amylin receptor for oral administration.

Strategic tierSecondaryTypeStrategic or Co-development Partner
Description

Collaboration on small-molecule PolQ polymerase domain inhibitors. Leveraged AI-generated ligand design from Iktos, with synthesis and evaluation expertise from Sygnature Discovery. Resulted in identification of a novel oxime-based scaffold and generation of highly potent functionalized oxime PolQ inhibitors with promising ADME properties. Published in ACS Omega.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Strategic collaboration deal with potential total value over €1 billion for co-development of drug candidates. Servier leverages Iktos's integrated AI and robotics platform for drug discovery programs. Represents Iktos's largest disclosed co-development partnership by value.

Strategic tierSecondaryTypeTechnology or Integration
Description

Iktos uses AWS cloud infrastructure for its AI-driven drug discovery platform. Featured in the AWS Pioneers Project, showcasing how Iktos leverages AWS cloud, AI agents, and generative AI to solve drug discovery challenges. Platform available on AWS with autoscaling capabilities.

Strategic tierSecondaryTypeStrategic or Co-development Partner
Description

Academic collaboration on peptide cheminformatics research, published in Drug Discovery Today (Elsevier). Joint research on computational approaches in peptide drug discovery covering representation, similarity assessments, machine/deep learning models, and peptide design.

Strategic tierSecondaryTypeStrategic or Co-development Partner
Description

Academic collaboration on peptide cheminformatics research, published in Drug Discovery Today (Elsevier). Joint research on computational tools to streamline peptide drug discovery.

Strategic tierSecondaryTypeStrategic or Co-development Partner
Description

Collaboration on large-scale compound selection guided by cell painting research published in Communications Biology (Springer-Nature). Research on phenotypic profiling for navigating chemical space using the JUMP-CP dataset and developing Phenoseeker web tool.

Recent move14 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Pioneer in AI-driven small-molecule drug discovery using generative design and active learning. Directly comparable to Iktos in offering generative AI design + automated synthesis + pharma collaborations, with a larger disclosed pipeline and public-company scale.

TypeDirect peer
Description

AI + robotics drug discovery combining quantum physics, ML, and automated synthesis labs. Strongest analog to Iktos on the AI-and-robotics integration angle, with a larger scale and broader CRO offering.

TypeDirect peer
Description

AI-driven small-molecule discovery using convolutional neural networks for structure-based design. Directly comparable to Iktos in target identification, hit generation, and pharma collaboration business model.

TypeDirect peer
Description

End-to-end AI drug discovery platform covering target ID, generative chemistry, and clinical development. Comparable to Iktos in combining AI-driven small-molecule design with internal pipeline programs and pharma partnerships, with deeper capital base.

TypeDirect peer
Description

Computational chemistry platform combining physics-based modeling (FEP+) with ML for small-molecule design. Comparable to Iktos as a software-and-services pharma R&D platform, with overlapping SaaS products and co-development deals.

TypeDirect peer
Description

AI platform for drug discovery combining knowledge graphs with ML to identify novel targets and molecules. Comparable to Iktos in operating a platform-plus-pipeline model serving pharma collaborators.

TypeEmerging player
Description

Robotics-driven drug discovery platform combining automated biology and chemistry with AI. Comparable to Iktos on the autonomous-lab integration thesis, at an earlier stage and narrower scope.

8Isomorphic Labs
TypeBroad incumbent
Description

Alphabet-owned AI drug discovery company spun out of DeepMind. Operates broadly across the same AI-driven small-molecule discovery space as Iktos but with vastly greater capital and computational resources.

TypeEmerging player
Description

Generative AI platform focused on protein and biologics design. Partially comparable to Iktos as a generative AI-for-discovery peer, though Cradle emphasizes biologics rather than small molecules.

TypeDirect peer
Description

AI-driven drug discovery combining high-throughput biology, automated labs, and foundation models. Directly comparable to Iktos in integrating automated experimentation with ML-driven design, with a stronger focus on phenotypic screening at industrial scale.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers9 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
Yes

Docs URL, Description

Integration4 records

Each record includes

Title, Type, Description, Source

AI capability8 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles14 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

iktos-dev

AI-Driven Drug Discovery Softwareiktos.com

Iktos is a Paris-based AI and robotics company developing Makya (generative AI drug design), Spaya (AI retrosynthesis), and Ilaka (robotic lab orchestration) into an integrated small-molecule drug discovery platform serving pharmaceutical, biotech, and academic partners globally.

What iktos-dev does

Iktos is a Paris-based AI and robotics company founded in 2016 that develops an integrated platform for small-molecule drug discovery spanning the full Design-Make-Test-Analyze (DMTA) cycle. Its three core products are Makya, a generative AI SaaS platform trained on millions of reactions that designs novel, synthetically accessible molecules with multi-parametric optimization across potency, selectivity, and ADMET properties; Spaya, an AI-driven retrosynthesis engine using reinforcement learning and Monte Carlo Tree Search to convert targets into commercially available starting materials in seconds; and Ilaka, an AI orchestration layer that transforms virtual molecules into executable instructions for Chemspeed robotic systems running 100+ reactions per day across 55+ named reactions. The Iktos Robotics Biology platform adds high-throughput phenotypic screening via the proprietary MTBench technology for protein-protein, RNA-protein, and molecular glue/PROTAC discovery, and the Iktos Engine APIs extend the stack with production-ready 3D design tools (Iktos 3D Align, Iktos 3D Dock, Boltz 3D Affinity).

The company generates revenue through three streams: SaaS subscriptions for Makya and Spaya (web and API access), fee-for-service and co-development drug discovery collaborations with pharmaceutical, biotech, and academic partners, and technology licensing — including transfer of Ilaka to pharma partners running Chemspeed robots. Pricing is quote-based and not publicly disclosed. Since founding, Iktos reports 60+ collaborations with major pharmaceutical companies (Merck, Pfizer, Servier, Janssen, Takeda, Pierre Fabre, Italfarmaco), biotech firms (Cube Biotech, Sygnature Discovery), and academic institutions, with one Servier strategic collaboration carrying potential total value exceeding €1 billion. Following a €15.5M Series A in 2023, Iktos has expanded into in-house drug discovery, maintaining a pipeline across MTHFD2 (inflammation/autoimmune), Amylin receptor (obesity/metabolism), and SKP2-CKS1 (immuno-oncology). Operations span Europe (Paris HQ), the United States, and Japan/APAC (Iktos K.K. subsidiary).

iktos-dev firmographics

Firmographics
Name
iktos-dev
Legal name
Iktos SA
Website
https://iktos.com
Company type
Private
Founded year
2016
Operating status
Operating
Short description
Iktos is a Paris-based AI and robotics company developing Makya (generative AI drug design), Spaya (AI retrosynthesis), and Ilaka (robotic lab orchestration) into an integrated small-molecule drug discovery platform serving pharmaceutical, biotech, and academic partners globally.
Ownership category
akta.pro rank

iktos-dev industry classification

Industry
Product category
AI-Driven Drug Discovery Software
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Computer Systems Design Services (541512)
SIC
Services-Commercial Physical & Biological Research (8731), Services-Computer Integrated Systems Design (7373)
akta.pro industry
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)

Keywords

  • Generative AI drug design
  • AI retrosynthesis planning
  • Automated drug discovery
  • AI-orchestrated laboratory automation
  • Computational chemistry platforms

Where iktos-dev is headquartered

Location

Headquarters

HQ city
Paris
HQ country
France
HQ region
Europe

Offices1 record

Markets served

iktos-dev business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Infrastructure, Marketing or Sales, Operations

Revenue model

  1. Drug Discovery Collaborations: Fee-for-service and co-development collaborations with pharmaceutical, biotech, and academic institutions for drug discovery programs. Partners engage Iktos to access AI-driven generative design, retrosynthesis planning, and robotic synthesis capabilities to advance their own programs from hit discovery through lead optimization. Collaboration structure includes both transactional service fees and potentially co-development arrangements with milestone payments.
  2. SaaS Platform Subscriptions (Makya, Spaya): Subscription-based access to Makya (generative AI drug design SaaS) and Spaya (AI-driven retrosynthesis SaaS) platforms. Platforms available via web interface and API access. Spaya API enables high-throughput scoring of synthetic feasibility for computational chemistry pipelines. Pricing likely subscription-based with potential usage-based API components.
  3. Technology Licensing and Integration: Licensing of Iktos technologies including Ilaka orchestration software for integration with third-party robotic platforms, and Spaya API for embedding in partner workflows. Technology transfer to pharmaceutical partners for deployment of AI-driven synthesis workflows.

Go-to-market motion1 record

Distribution channels6 records

Marketing channels9 records

iktos-dev product offering

Product offering

Core offering

Iktos develops and sells an integrated AI and robotics platform for small-molecule drug discovery. Its core offerings are the Makya generative AI SaaS for de novo molecular design, the Spaya AI-driven retrosynthesis SaaS, the Ilaka orchestration software that connects designs to Chemspeed robotic synthesis, and the Iktos Engine APIs for 3D drug design. The platform enables pharmaceutical and biotech partners to execute the full Design-Make-Test-Analyze (DMTA) cycle.

Product overview

Iktos offers an integrated AI and robotics platform for drug discovery comprising three core products: Makya (generative AI for de novo molecular design), Spaya (AI-driven retrosynthesis planning), and Ilaka/Iktos Robotics (AI-orchestrated laboratory automation). The platform operates as a unified DMTA (Design-Make-Test-Analyze) cycle, where Makya generates optimized molecules, Spaya identifies synthesis routes, and Ilaka coordinates robotic execution. Additional offerings include Iktos Engine APIs for 3D drug design and MTBench for phenotypic screening. The company also maintains an internal pipeline of drug candidates in oncology, inflammation, and metabolism.

Differentiator

Problem solved

Functional benefit

Products and services

  • Makya Makya is a generative AI SaaS platform for de novo small-molecule drug design. It creates diverse, novel, and synthetically accessible medchem-like molecules using multi-parametric optimization, 3D ligand-based and structure-based modeling, SAR modeling, and ADMET property optimization. It is targeted at medicinal and computational chemistry teams in pharmaceutical and biotech companies.
  • Spaya Spaya is an AI-driven retrosynthesis SaaS platform that identifies feasible synthetic routes by converting target compounds into commercially available starting materials in seconds. It uses reinforcement learning and Monte Carlo Tree Search, supports 35+ provider partnerships, 2000+ named reactions, customizable constraints, and chirality handling. It is used by computational chemistry teams in pharma and biotech for synthetic feasibility scoring.
  • Ilaka Ilaka is an AI-driven laboratory orchestration software that transforms virtual molecules into executable instructions for Chemspeed robotic systems. It orchestrates the full decision workflow from retrosynthesis and reaction selection to reagent sourcing, experimental procedures, and synthesis scheduling, including AI-driven reaction clustering for parallel execution. It is licensed to pharmaceutical partners seeking to deploy AI-orchestrated laboratory automation.
  • Iktos Engine APIs Iktos Engine APIs are production-ready APIs for 3D drug design workflows. The suite includes Iktos 3D Align for template-based ligand alignment, Iktos 3D Dock for pocket-aware template-based docking, and Boltz 3D Affinity for binding affinity prediction. The APIs address ligand-based and structure-based design decisions across hit-to-lead optimization projects and integrate with Knime, Pipeline Pilot, and Jupyter Notebook.
  • Iktos Robotics Chemistry and Biology Iktos Robotics is a fully automated synthesis, purification, and analysis platform using Chemspeed robotics, capable of running 100 reactions per day in parallel across more than 55 different named reactions. Iktos Robotics Biology includes high-throughput phenotypic assays using patented Microtubule Bench technology for in-cellulo screening of protein-protein interactions, RNA-protein interactions, and molecular glues/PROTACs.

Quantifiable outcome

  • Discovery phase timeline reduced from 4-5 years to under 2 years for preclinical candidate identification
  • +6 more outcomes

Companies that use iktos-dev

Customer profile

Named customers9 records

Segments4 records

Ideal customer profiles3 records

iktos-dev technology and API

Technology

Technology focussed Yes

API detail

Has API
Yes
API docs
API detail

Core technology

AI maturity

App detail

Integration4 records

AI capability8 records

Feature6 records

iktos-dev partnerships and signals

Strategic signal

Partnerships

Nine partnerships are on record, tiered core and secondary.

  • Chemspeed Technologies (a Bruker company)coreTechnology or Integration · 26 March 2026Collaboration to offer pharmaceutical partners a solution combining advanced synthesis planning and orchestration AI software with Chemspeed robotics for chemical synthesis execution. Iktos makes available the Ilaka AI-driven laboratory orchestration technology developed for the Chemspeed chemistry automation platform. Ilaka transforms virtual molecules into executable instructions for Chemspeed robotic systems, orchestrating the full decision workflow from retrosynthesis to reagent sourcing, experimental procedures, and synthesis scheduling. Partnership enables technology transfer to pharmaceutical partners seeking to deploy AI-orchestrated laboratory automation.
  • Elsevier (Reaxys)coreTechnology or IntegrationStrategic partnership combining the world's largest chemistry database Reaxys with Iktos's cutting-edge AI retrosynthesis technology to create new predictive retrosynthesis and synthetic accessibility tools. Integrates Elsevier's chemistry data infrastructure with Iktos's Spaya platform capabilities.
  • Cube BiotechcoreStrategic or Co-development PartnerPartnership to co-develop novel Amylin receptor agonists for obesity and cardiometabolic disorders. Cube's cutting-edge protein stabilization technology preserves the natural conformation of membrane proteins, enabling access to biologically active drug targets. Combined with Iktos's AI-driven drug discovery platform, this collaboration aims to accelerate development of breakthrough small molecule therapies targeting the Amylin receptor for oral administration.
  • Sygnature DiscoverysecondaryStrategic or Co-development PartnerCollaboration on small-molecule PolQ polymerase domain inhibitors. Leveraged AI-generated ligand design from Iktos, with synthesis and evaluation expertise from Sygnature Discovery. Resulted in identification of a novel oxime-based scaffold and generation of highly potent functionalized oxime PolQ inhibitors with promising ADME properties. Published in ACS Omega.
  • ServiercoreStrategic or Co-development PartnerStrategic collaboration deal with potential total value over €1 billion for co-development of drug candidates. Servier leverages Iktos's integrated AI and robotics platform for drug discovery programs. Represents Iktos's largest disclosed co-development partnership by value.
  • AWS (Amazon Web Services)secondaryTechnology or IntegrationIktos uses AWS cloud infrastructure for its AI-driven drug discovery platform. Featured in the AWS Pioneers Project, showcasing how Iktos leverages AWS cloud, AI agents, and generative AI to solve drug discovery challenges. Platform available on AWS with autoscaling capabilities.
  • ETH ZurichsecondaryStrategic or Co-development PartnerAcademic collaboration on peptide cheminformatics research, published in Drug Discovery Today (Elsevier). Joint research on computational approaches in peptide drug discovery covering representation, similarity assessments, machine/deep learning models, and peptide design.
  • Novo NordisksecondaryStrategic or Co-development PartnerAcademic collaboration on peptide cheminformatics research, published in Drug Discovery Today (Elsevier). Joint research on computational tools to streamline peptide drug discovery.
  • Institut Curie / INSERM / IBENS / Ecole Normale Superieure / Mines ParisTech / Universite Paris Cite / Biophenics LaboratorysecondaryStrategic or Co-development PartnerCollaboration on large-scale compound selection guided by cell painting research published in Communications Biology (Springer-Nature). Research on phenotypic profiling for navigating chemical space using the JUMP-CP dataset and developing Phenoseeker web tool.

Scale indicators9 records

Recent moves14 records

Expansion highlights7 records

iktos-dev competitors and assessment

Company assessment

Direct peers

  • Exscientia: Pioneer in AI-driven small-molecule drug discovery using generative design and active learning. Directly comparable to Iktos in offering generative AI design + automated synthesis + pharma collaborations, with a larger disclosed pipeline and public-company scale.
  • XtalPi: AI + robotics drug discovery combining quantum physics, ML, and automated synthesis labs. Strongest analog to Iktos on the AI-and-robotics integration angle, with a larger scale and broader CRO offering.
  • Atomwise: AI-driven small-molecule discovery using convolutional neural networks for structure-based design. Directly comparable to Iktos in target identification, hit generation, and pharma collaboration business model.
  • Insilico Medicine: End-to-end AI drug discovery platform covering target ID, generative chemistry, and clinical development. Comparable to Iktos in combining AI-driven small-molecule design with internal pipeline programs and pharma partnerships, with deeper capital base.
  • Schrödinger: Computational chemistry platform combining physics-based modeling (FEP+) with ML for small-molecule design. Comparable to Iktos as a software-and-services pharma R&D platform, with overlapping SaaS products and co-development deals.
  • BenevolentAI: AI platform for drug discovery combining knowledge graphs with ML to identify novel targets and molecules. Comparable to Iktos in operating a platform-plus-pipeline model serving pharma collaborators.
  • Recursion: AI-driven drug discovery combining high-throughput biology, automated labs, and foundation models. Directly comparable to Iktos in integrating automated experimentation with ML-driven design, with a stronger focus on phenotypic screening at industrial scale.

Emerging players

  • Arctoris: Robotics-driven drug discovery platform combining automated biology and chemistry with AI. Comparable to Iktos on the autonomous-lab integration thesis, at an earlier stage and narrower scope.
  • Cradle Bio: Generative AI platform focused on protein and biologics design. Partially comparable to Iktos as a generative AI-for-discovery peer, though Cradle emphasizes biologics rather than small molecules.

Broad incumbents

  • Isomorphic Labs: Alphabet-owned AI drug discovery company spun out of DeepMind. Operates broadly across the same AI-driven small-molecule discovery space as Iktos but with vastly greater capital and computational resources.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

iktos-dev social profiles

Digital presence

iktos-dev financial estimates

Financial estimate

Revenue estimate

Valuation estimate

iktos-dev leadership team

Management profile

Number of profiles

Profiles14 records

iktos-dev subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

iktos-dev funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

iktos-dev M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about iktos-dev

What does iktos-dev do?

Iktos develops and sells an integrated AI and robotics platform for small-molecule drug discovery. Its core offerings are the Makya generative AI SaaS for de novo molecular design, the Spaya AI-driven retrosynthesis SaaS, the Ilaka orchestration software that connects designs to Chemspeed robotic synthesis, and the Iktos Engine APIs for 3D drug design. The platform enables pharmaceutical and biotech partners to execute the full Design-Make-Test-Analyze (DMTA) cycle.

Is iktos-dev a public or private company?

iktos-dev is a private company. It is classified as venture growth investor backed and is currently operating.

When was iktos-dev founded?

iktos-dev was founded in 2016.

Where is iktos-dev based?

iktos-dev is headquartered in Paris, France, in the Europe region.

How does iktos-dev make money?

Three revenue lines are on record. Drug Discovery Collaborations are the primary driver. The others are saaS Platform Subscriptions (Makya, Spaya) and technology Licensing and Integration.

Who are iktos-dev's main competitors?

Direct peers on record are Exscientia, XtalPi, Atomwise, Insilico Medicine, Schrödinger, BenevolentAI and Recursion. Emerging players are Arctoris and Cradle Bio. Isomorphic Labs is listed as a broad incumbent.

Does iktos-dev have an API?

Yes. Iktos offers multiple APIs including: (1) Spaya API for high-throughput scoring of synthetic feasibility with RScore, Number of Steps, and RSpred Score; (2) Iktos Engine APIs including Iktos 3D Align for ligand alignment, Iktos 3D Dock for template-based docking, and Boltz 3D Affinity for binding affinity prediction. APIs are available on AWS with autoscaling or on customer VPC. Integrates with platforms like Knime, Pipeline Pilot, and Jupyter Notebook. Developer documentation is at github.com/iktos/engine.

What industry is iktos-dev in?

iktos-dev's product category is AI-Driven Drug Discovery Software. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization. Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales